Stephen Seiler is CEO of AesRx, a company he founded in 2009 to develop orphan drugs. Prior to founding AesRx, he was CEO of several public and private biotech companies that he successfully led through restructuring and refinancing and/or trade sales, including Idera Pharmaceuticals, Access Pharmaceuticals and Effective Pharmaceuticals. Before that, Seiler was executive vice president for planning, investment and development at Elan Corp. Plc., helping to transform Elan from a small drug delivery company (with 1996 revenues of $200 million) into a fully integrated specialty pharmaceutical company (with 2000 revenues of $1.5 billion). Previously Seiler worked as an investment banker in New York and London, including founding and heading the pharmaceutical industry investment banking group for Paribas Capital Markets. He is on the Board of Associates of the Whitehead Institute for Biomedical Research. Seiler received a J.D. from Georgetown University and a B.A. from the University of Notre Dame.

Panel:
Purpose and Partners: Yielding Return on Medical Research Investments

Tweet